Particle.news
Download on the App Store
7 ARTICLES
·
7mo ago

USFDA Accepts Wockhardt’s NDA for Novel Antibiotic Zaynich as Stock Rallies

The acceptance triggers a Fast Track review that begins the regulatory evaluation rather than granting marketing approval.

Image
"This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA," the company stated.
Image
Image

Overview

  • Wockhardt announced the US regulator has accepted its New Drug Application for Zaynich, a first-in-class antibiotic targeting resistant infections.
  • The company says this marks the first time an Indian pharma NCE has had an NDA filed and accepted by the USFDA.
  • Shares jumped sharply on Monday and extended gains on Tuesday following the announcement of the regulatory milestone.
  • Wockhardt filed the NDA on September 30, 2025, after a development program it says began in 2011 and has produced extensive non-clinical and clinical data.
  • Zaynich has USFDA Fast Track designation, and while some reports cite strong trial outcomes, those efficacy claims remain subject to the FDA’s full review and are not approvals.